Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Charles River Labs (CRL) Pulled Back Due to AI Disruption Fears - Insider Monkey

AI-generated analysis

📉 Charles River Laboratories (CRL) saw its shares pull back in Q1 2026 as the Madison Small Cap Fund's healthcare sector underperformed.

💰 The fund attributes the decline to market volatility and fears that AI will disrupt drug development services.

🛡️ Fund managers argue that AI disruption fears are overexaggerated and that CROs like CRL have ample resources to capture value from AI tools.

⚙️ Implementation of AI is expected to shorten trial timelines, improve clinical submissions, and increase demand for clinical research services.

📈 Despite the pullback, the Madison Small Cap Fund has selectively added to its positions in Charles River Laboratories.

📊 CRL closed at $188.06 per share on June 11, 2026, with a market capitalization of $9.06 billion.

📉 Hedge fund holdings for CRL decreased from 53 portfolios in the previous quarter to 43 at the end of Q1 2026.

🤖 The fund believes larger CROs are better positioned than smaller peers to implement AI tools effectively.

🔍 The article references a separate report claiming other AI stocks have greater promise for delivering higher returns.

Bullish Signals
  • The Madison Small Cap Fund remains enthusiastic about its investments in Charles River Laboratories despite recent price pullbacks.
  • Fund managers believe that AI implementation will lead to more viable drug candidates and an increase in demand for clinical research services.
  • Larger CROs like Charles River have ample resources to capture value from AI tools for both themselves and their clients.
  • AI adoption is expected to improve program design times, shorten trial timelines, and improve clinical submissions.
  • The fund has selectively added to its positions in Charles River Laboratories during the first quarter of 2026.
Risk Factors
  • Charles River Laboratories was part of the fund's worst-performing sector (Healthcare) in the first quarter of 2026.
  • The stock experienced a pullback driven by market fears that AI will disrupt drug development services.
  • Hedge fund interest in CRL declined, with portfolio holdings dropping from 53 to 43 between the previous quarter and Q1 2026.
Full Analysis
Madison Small Cap Fund released its Q1 2026 investor letter, noting that while the fund slightly underperformed benchmarks, it maintained a preference for quality value stocks. The fund specifically highlighted Charles River Laboratories International (CRL) as a position that pulled back in the first quarter due to market fears regarding AI disruption within the healthcare sector. Despite the pullback, the fund's strategy team argues that fears of AI replacing drug development are exaggerated. They believe AI tools will improve efficiency and program design times for contract research organizations (CROs) like CRL, leading to more viable drug candidates rather than reduced spending. Consequently, the fund remains enthusiastic about these investments and has selectively added to its positions in CRL. The article notes that 43 hedge fund portfolios held CRL at the end of Q1 2026, down from 53 in the previous quarter. The fund manager suggests that while CRL is a solid investment, other AI stocks may offer higher returns and shorter time frames, though they do not view CRL as lacking promise.